Clinical outcomes of coronavirus disease 2019 (COVID‐19) in cancer patients with prior exposure to immune checkpoint inhibitors

Clinical outcomes of coronavirus disease 2019 (COVID‐19) in cancer patients with prior exposure to immune checkpoint inhibitors

Bibliographic Details
Main Authors:	Qiuji Wu, Qian Chu, Hongyan Zhang, Bin Yang, Xudong He, Yahua Zhong, Xianglin Yuan, Melvin L.K. Chua, Conghua Xie
Format:	Article
Language:	English
Published:	Wiley 2020-08-01
Series:	Cancer Communications
Online Access:	https://doi.org/10.1002/cac2.12077

Similar Items

Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy
by: Ioana Plesca, et al.
Published: (2020-03-01)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
by: Vikki Tang, et al.
Published: (2021-02-01)

Potential inhibitor for 2019-novel coronaviruses in drug development
by: Xiaohui Xu, et al.
Published: (2020-01-01)

Update on association between exposure to renin-angiotensin-aldosterone system inhibitors and coronavirus disease 2019 in South Korea
by: Jeongkuk Seo, et al.
Published: (2021-03-01)

Gut microbiome modulates efficacy of immune checkpoint inhibitors
by: Ming Yi, et al.
Published: (2018-03-01)

Safety and potential efficacy of cyclooxygenase‐2 inhibitors in coronavirus disease 2019
by: Sean Wei Xiang Ong, et al.
Published: (2020-01-01)

The Effect of Chronic and Inhospital Exposure to Renin-Angiotensin System Inhibitors on the Outcome and Inflammatory State of Coronavirus Disease 2019 Adult Inpatients
by: Pedro Gaspar, et al.
Published: (2021-01-01)

Cardiotoxicity and Mechanisms of Immune Checkpoint Inhibitors
by: DONG Shuang, et al.
Published: (2018-11-01)

Epidemiological and clinical differences of coronavirus disease 2019 patients with distinct viral exposure history
by: Yinjie Gao, et al.
Published: (2020-01-01)

A retrospective analysis on metastatic rate of the internal mammary lymph node and its clinical significance in adjuvant radiotherapy of breast cancer patients
by: Li Li, et al.
Published: (2020-02-01)

Checkpoint Inhibitors and Hepatotoxicity
by: Stephen D. H. Malnick, et al.
Published: (2021-01-01)

In silico exploration of novel protease inhibitors against coronavirus 2019 (COVID-19)
by: Elham Aghaee, et al.
Published: (2021-01-01)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
by: Zhaozhen Wu, et al.
Published: (2021-02-01)

Systematic Profiling of Immune Risk Model to Predict Survival and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
by: Xingyu Liu, et al.
Published: (2020-10-01)

Impact of treatment delay due to the pandemic of COVID-19 on the efficacy of immunotherapy in head and neck cancer patients
by: Gaili Chen, et al.
Published: (2020-12-01)

Feasibility of coronavirus disease 2019 eradication
by: Ya-Li Zheng, et al.
Published: (2020-06-01)

Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors
by: Noelia Vilariño, et al.
Published: (2020-08-01)

Epidemiological Trends of Coronavirus Disease 2019 in China
by: Bilin Chen, et al.
Published: (2020-05-01)

Bone remodeling by checkpoint inhibitor
by: Hyeongjong Kim, et al.
Published: (2020-09-01)

Determinants of Resistance to Checkpoint Inhibitors
by: Linda Tran, et al.
Published: (2020-02-01)

Immune Checkpoint Inhibitors and the Heart
by: Diana Larisa Mocan-Hognogi, et al.
Published: (2021-09-01)

Checkpoint inhibitors in hematological malignancies
by: Chi Young Ok, et al.
Published: (2017-05-01)

Development of a coronavirus disease 2019 nonhuman primate model using airborne exposure.
by: Sara C Johnston, et al.
Published: (2021-01-01)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
by: Chenxin Chen, et al.
Published: (2021-02-01)

Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)
by: Caicun ZHOU, et al.
Published: (2020-02-01)

Prevention, susceptibility, and clinical features of coronavirus disease 2019 in postoperative patients
by: Yuan Gao, et al.
Published: (2020-12-01)

Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
by: Ghayathri Jeyakumar, et al.
Published: (2017-10-01)

Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model
by: Hua-Hao Fan, et al.
Published: (2020-05-01)

Role of antibiotics in coronavirus 2019
by: Gehan Elassal, et al.
Published: (2021-01-01)

Coronavirus disease COVID-2019
by: B. K. Romanov
Published: (2020-03-01)

Coronavirus Disease 2019 and Stroke
by: Jong S. Kim
Published: (2020-05-01)

Coronavirus disease 2019 and the kidney
by: Ravi Jangamani, et al.
Published: (2020-01-01)

Coronavirus disease 2019 in pregnancy
by: Xu Qiancheng, et al.
Published: (2020-06-01)

Nephrology and Coronavirus Disease 2019
by: Joyita Bharati, et al.
Published: (2020-07-01)

Coronavirus Disease 2019 in Children
by: Melissa Borrelli, et al.
Published: (2021-05-01)

Coronavirus disease 2019 in pregnancy
by: Mi Tang, et al.
Published: (2021-04-01)

Immune Checkpoint Inhibitors New Insights and Recent Progress
Published: (2023)

Virtual Evolution of HVEM Segment for Checkpoint Inhibitor Discovery
by: Mingjia Yu, et al.
Published: (2021-06-01)

Acute Kidney Injury in the 2019 Novel Coronavirus Disease
by: Jing-Yi Qian, et al.
Published: (2020-06-01)

Erratum: Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)
by: Editorial Office of Chinese Journal of Lung Cancer
Published: (2020-03-01)

Cannot write session to /tmp/vufind_sessions/sess_vuskvicblnaro5l9ikjskiiaba